CN103181894B - Nabumetone spraying agent and preparation method - Google Patents
Nabumetone spraying agent and preparation method Download PDFInfo
- Publication number
- CN103181894B CN103181894B CN201110456544.5A CN201110456544A CN103181894B CN 103181894 B CN103181894 B CN 103181894B CN 201110456544 A CN201110456544 A CN 201110456544A CN 103181894 B CN103181894 B CN 103181894B
- Authority
- CN
- China
- Prior art keywords
- nabumetone
- weight
- spray
- penetration enhancer
- transdermal penetration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a nabumetone spraying agent and a preparation method. The nabumetone spraying agent comprises nabumetone, a transdermal penetrating agent and an excipient. The nabumetone spraying has the advantages of fast absorption, safe drug usage and convenient usage, can avoid large liver first-pass effect of a nabumetone oral preparation, and can avoid the stimulation generated by continuous administration for gastrointestinal tract.
Description
Technical field
The invention belongs to pharmaceutical field, in particular to nabumetone spray and preparation method thereof.
Background technology
Nabumetone (has another name called Nabumetone, nabumetone), chemistry 4-(6-methoxyl group-2-naphthyl)-Ding-2-ketone by name, it is the nonacid NSAID (non-steroidal anti-inflammatory drug) of one of Beecham company of Britain research and development, in Initial Public Offering (trade name: Relifex, BRL-14777) in 1985.This medicine has analgesia, the refrigeration function of good anti-inflammatory activity and middle intensity, and toxic and side effects is little, has good toleration, can be used for various types of rheumatic arthritis, tendinitis, cervical spondylitis, soft tissue rheumatism, and the pain caused by these diseases; It also can be used for soft tissue injury due to sport, sprain and contusion etc., and pain caused by these diseases and inflammation.It is owing to having exclusive pharmacological property and the favor of extremely patient and doctor.
Domestic and international existing listing dosage form is oral solid formulation (such as capsule, tablet, granule etc.), and this dosage form taking dose is large, patient's dysphagia, and taking continuously to produce gastrointestinal tract stimulates.Consider these reasons, be necessary to develop a kind of other suitable route of administration except oral route.Transdermal delivery system is an emerging field in pharmaceutics, and drug percutaneous skin is surperficial and diffuse through epidermis arrival dermal tissue, and after epidermal area, some drugs is transported to rapidly in microcirculation.Due to the barrier action of human skin keratinocyte's layer, the skin permeation amount of many medicines can not meet the object for the treatment of.At present, scientific and technical literature " preparation technique " (the 9th volume the 8th phase in 2000) discloses a kind of preparation method and quality control thereof of nabumetone liniment, but the method, only simply by medicine dissolution, fails to improve the skin permeation rates of medicine.
Summary of the invention
For solving problem existing in above-mentioned prior art, the invention provides a kind of nabumetone spray of applied dermally, and the preparation method of nabumetone spray.
Specifically, the invention provides:
(1) a nabumetone spray, it comprises: nabumetone, transdermal penetration enhancer and excipient.
(2) the nabumetone spray Gen Ju (1), wherein said transdermal penetration enhancer be selected from azone, oleic acid, propylene glycol, terpenoid substance one or more.
(3) the nabumetone spray Gen Ju (1), wherein said transdermal penetration enhancer be selected from azone, oleic acid and propylene glycol one or more.
(4) according to the nabumetone spray according to any one of (1)-(3), wherein said excipient comprises solvent and solubilizing agent.
(5) the nabumetone spray Gen Ju (4), wherein said solubilizing agent be selected from sodium lauryl sulphate, Tween 80 and PEG400 one or more.
(6) the nabumetone spray Gen Ju (5), wherein said solubilizing agent is PEG400.
(7) the nabumetone spray Gen Ju (4), wherein said solvent is the ethanol water of 50-100 volume %.
(8) the nabumetone spray Gen Ju (1), wherein, based on the total amount of described nabumetone spray, the amount of described nabumetone is 1 % by weight to 8 % by weight, the amount of described transdermal penetration enhancer is 1 % by weight to 5 % by weight, and the amount of described excipient is 87 % by weight to 98 % by weight.
(9) the nabumetone spray Gen Ju (4), wherein, based on the total amount of described nabumetone spray, the amount of described solubilizing agent is 5 % by weight to 60 % by weight, and the amount of described solvent is 30 % by weight to 90 % by weight.
(10) one prepares the method for the nabumetone spray according to any one of (1)-(9), and the method comprises: 1) by even to nabumetone, transdermal penetration enhancer and mixed with excipients; 2) by step 1) the mixture fill that obtains is in aerosol container.
The present invention compared with prior art has the following advantages and good effect:
1. the invention provides a kind of nabumetone spray, it can applied dermally, thus the liver first-pass effect overcoming nabumetone oral formulations is comparatively large, takes continuously and can produce the shortcomings such as stimulation to gastrointestinal tract, its drug safety, easy to use.
2. the present invention is by selecting suitable transdermal penetration enhancer further, improves drug penetration through skin rate, and transdermal penetration, absorption soon, thus add the bioavailability of effective ingredient well to enable nabumetone.
3. the present invention is by selecting suitable solubilizing agent further, improve drug solubility, in ethanol under making nabumetone can be dissolved in room temperature, which ensure that the concentration of active constituents of medicine, avoid simultaneously and nabumetone is dissolved in the high chloroform of dissolubility wherein and benzene etc. in the solvent of human body generation toxic and side effects.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The invention provides nabumetone spray, and the preparation method of nabumetone spray.The present inventor have selected the suitable transdermal penetration enhancer for nabumetone spray, and have selected suitable excipient (comprising (such as) solubilizing agent and solvent), thus make nabumetone can percutaneous absorbtion well, and drug safety, easy to use.
Specifically, one aspect of the present invention provides a kind of nabumetone spray, and it comprises active ingredient, transdermal penetration enhancer and excipient, and wherein said active ingredient is nabumetone.
As described in the background art, current nabumetone is oral solid formulation, and this dosage form taking dose is large, patient's dysphagia, and taking continuously to produce gastrointestinal tract stimulates.Therefore this invention exploits can the nabumetone spray of applied dermally.Concerning the preparation of applied dermally, the Cutaneous permeation barrier that human skin keratinocyte's layer brings is the large obstacle obtaining good biological availability.Therefore, in nabumetone spray of the present invention, transdermal penetration enhancer is added.
In this article, " transdermal penetration enhancer " refers to, it can promote the surface activity of percutaneous drug absorption.
In this article, " ethanol waters of 100 volume % " refer to dehydrated alcohol.
In the present invention, the example of operable transdermal penetration enhancer comprises the conventional transdermal penetration enhancer in this area, such as azone, oleic acid, terpenoid substance, ethanol and propylene glycol etc.
In the present invention, transdermal penetration enhancer can be selected from azone, oleic acid, propylene glycol and/or terpenoid substance.Wherein terpenoid substance comprises (such as) Borneolum Syntheticum and menthol.
In a preferred embodiment in accordance with this invention, transdermal penetration enhancer be selected from one in azone, propylene glycol, oleic acid, two or more.
In the present invention, excipient can comprise solvent and solubilizing agent.
Nabumetone is dissolved in the ethanol of chloroform, benzene and heat, is slightly soluble in ethanol at normal temperatures, water insoluble.But chloroform, benzene etc., to human body toxic side effect, can not use as solvent; And be difficult to the temperature making ethanol maintenance heat in actual applications.Therefore, when adopting ethanol as solvent, for increasing the dissolubility of nabumetone, ensureing the concentration of active constituents of medicine, solubilizing agent need be added to improve its dissolubility.In addition, the aqueous solution of ethanol can also be adopted as solvent, such as, adopt the ethanol water of 50-100 volume %, more preferably adopt the ethanol water of 70-100 volume %; Preferably adopt the ethanol water of 95 volume % further.When adopting the aqueous solution of ethanol as solvent, also need to add solubilizing agent to improve its dissolubility.
In the present invention, the example of operable solubilizing agent comprises the conventional solubilizing agent in this area, such as sodium lauryl sulphate, Tweens, polyethylene glycols etc.
In one embodiment of the invention, solubilizing agent is selected from sodium lauryl sulphate, Tween 80 and PEG400.
In a preferred embodiment in accordance with this invention, solubilizing agent is PEG400.
Usually, along with the consumption of transdermal penetration enhancer increases, it is to the zest of skin also corresponding increase.In order to obtain good skin permeation rates, keep low skin lesion degree, the amount of transdermal penetration enhancer needs to remain in suitable scope simultaneously.
Preferably, in the present invention, based on the total amount of nabumetone spray, the amount of described nabumetone is 1 % by weight to 8 % by weight, and the amount of described transdermal penetration enhancer is 1 % by weight to 5 % by weight, and the amount of described excipient is 87 % by weight to 98 % by weight; More preferably, the amount of described excipient is 89 % by weight to 96 % by weight.
More preferably, based on the total amount of described nabumetone spray, the amount of described solubilizing agent is 5 % by weight to 60 % by weight, and the amount of described solvent is 30 % by weight to 90 % by weight.
In another aspect of the present invention, nabumetone spray of the present invention can be used for treating various types of rheumatic arthritis, tendinitis, cervical spondylitis, soft tissue rheumatism, and the pain caused by these diseases; It also can be used for treatment soft tissue injury due to sport, sprains and contusion etc., and pain caused by these diseases and inflammation.
Another aspect of the present invention provides the method preparing nabumetone spray, and the method comprises: 1) by even to nabumetone, transdermal penetration enhancer and mixed with excipients; 2) by step 1) the mixture fill that obtains is in aerosol container.
The conventional packaging process in this area is, utilizes spray filling machine by medicinal mixture fill in aerosol container, carries out spiral cover and packaging afterwards.Conventional spray filling machine (as (rolling) lid machine is revolved in spray fill) can be adopted by above-mentioned steps 1) the mixture fill that obtains in aerosol container, and carries out spiral cover packaging.
Mode below by way of example further explains and describes content of the present invention, but these examples should not be understood to the restriction to protection scope of the present invention.
Example
In following example, nabumetone used can derive from SouthWest Synthetic Pharmaceutical Corp. Ltd; PEG400 can derive from Chengdu Ke Long chemical reagent factory; Azone can derive from Xing Qing chemical plant, Ruicheng, Shanxi; Propylene glycol can derive from Anhui Yi Pu Chemical Co., Ltd.; Oleic acid can derive from Huai'an Dong Bao oils and fats Manufacturing Co., Ltd; 95% ethanol (i.e. the ethanol water of 95 volume %) can derive from Chongqing Chuan Dong chemical industry (group) company limited; Borneolum Syntheticum can derive from Zhengzhou Lan Yu Chemical Co., Ltd.; Menthol can derive from the grand perfumery oil company limited in Ji'an, Jiangxi.Aerosol container can derive from Zhengzhou, henan city Kai Wei blister plastic packaging factory; Filling apparatus adopts the fill of GDGXP type spray to revolve (rolling) lid machine, can derive from Chengdu Geng De package packing machine company limited.
Embodiment 1
Get 1.0g nabumetone, be dissolved in the mixed solution of 45g 95% ethanol and 5g PEG400, add 1.0g azone, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Embodiment 2
Get 2.0g nabumetone, be dissolved in the mixed solution of 40g 95% ethanol and 10g PEG400, add 2.0g azone, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 2.0g nabumetone, can use 100 times.
Embodiment 3
Get 3.0g nabumetone, be dissolved in the mixed solution of 30g 95% ethanol and 20g PEG400, add 1.0g azone, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 3.0g nabumetone, can use 100 times.
Embodiment 4
Get 4.0g nabumetone, be dissolved in the mixed solution of 30g 95% ethanol and 20g PEG400, add 1.0g azone, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 4.0g nabumetone, can use 100 times.
Embodiment 5
Get 1.0g nabumetone, be dissolved in the mixed solution of 30g 95% ethanol and 20g PEG400, add 0.5g azone and 0.5g propylene glycol, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Embodiment 6
Get 4.0g nabumetone, be dissolved in the mixed solution of 30g 95% ethanol and 20g PEG400, add 0.5g azone and 0.5g propylene glycol, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 4.0g nabumetone, can use 100 times.
Embodiment 7
Get 1.0g nabumetone, be dissolved in the mixed solution of 30g 95% ethanol and 20g PEG400, add 1.0g propylene glycol, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Embodiment 8
Get 1.0g nabumetone, be dissolved in the mixed solution of 30g 95% ethanol and 20g PEG400, add 1.0g propylene glycol and 1.0g azone, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Embodiment 9
Get 4.0g nabumetone, be dissolved in the mixed solution of 20g 95% ethanol and 30g PEG400, add 1.0g propylene glycol and 1.0g azone, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 4.0g nabumetone, can use 100 times.
Embodiment 10
Get 1.0g nabumetone, be dissolved in the mixed solution of 30g 95% ethanol and 20g PEG400, add 0.5g propylene glycol and 0.5g oleic acid, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Embodiment 11
Get 4.0g nabumetone, be dissolved in the mixed solution of 25g 95% ethanol and 25g PEG400, add 0.5g azone and 0.5g oleic acid, fully mix, fill is afterwards in 60ml aerosol container, and packaging completes.Every bottle, containing 4.0g nabumetone, can use 100 times.
Embodiment 12
Get 1.0g nabumetone, be dissolved in the mixed solution of 25g 95% ethanol and 25g PEG400, add 0.5g azone and 0.5g oleic acid, fully mix, fill is in aerosol container afterwards, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Embodiment 13
Get 1.0g nabumetone, be dissolved in the mixed solution of 25g 95% ethanol and 25g PEG400, add 0.33g propylene glycol, 0.33g azone and 0.33g oleic acid, fully mix, fill is in aerosol container afterwards, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Embodiment 14
Get 1.0g nabumetone, be dissolved in the mixed solution of 25g 95% ethanol and 25g PEG400, add 1.0g Borneolum Syntheticum, fully mix, fill is in aerosol container afterwards, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Embodiment 15
Get 1.0g nabumetone, be dissolved in the mixed solution of 25g 95% ethanol and 25g PEG400, add 1.0g menthol, fully mix, fill is in aerosol container afterwards, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Comparative example 1
Get 1.0g nabumetone, be dissolved in the mixed solution of 25g 95% ethanol and 25g PEG400, fully mix, fill is in aerosol container afterwards, and packaging completes.Every bottle, containing 1.0g nabumetone, can use 100 times.
Test example 1: the selection of solubilizing agent
At room temperature, 1.0g sodium lauryl sulphate, 1.0g Tween 80 and 1.0g PEG400 are added in the container filling 100g ethanol respectively, with the incremental gradient of each 0.5g, nabumetone is added wherein respectively, jolting, place, observe the meltage of nabumetone.Experimental result shows, when solubilizer level is identical, the solubilizing effect of PEG400 is best.Experimental result is as shown in table 1 below.
Table 1
Test example 2: the selection of transdermal penetration enhancer
The skin of obtained nabumetone spray to the identical joint part of experimenter is carried out spray test, after each spraying half an hour, carries out acess control.During same site tests to same experimenter, at least test next time is carried out at interval for 24 hours again, and after test at every turn, with ethanol purge and the skin of dry tested joint part, then carries out next time and tests.Be specially:
The made nabumetone spray of embodiment 1, embodiment 5, embodiment 7, embodiment 10 is adopted to test 36 routine experimenters, not add the comparative example 1 of any above-mentioned transdermal penetration enhancer in contrast, result shows, the experimenter of 94.4% thinks that the drug permeability adding transdermal penetration enhancer strengthens, and without obvious skin irritation.
The made nabumetone spray of embodiment 1, embodiment 7, embodiment 14, embodiment 15 is adopted to test the above-mentioned experimenter's (34 example) thinking that drug permeability strengthens, result shows, and the experimenter of 94.1% thinks the effect of azone, propylene glycol, and comparatively Borneolum Syntheticum, menthol are good.
The made nabumetone spray of embodiment 5, embodiment 10, embodiment 12, embodiment 13 is adopted to test the above-mentioned experimenter's (34 example) thinking that drug permeability strengthens, result shows, and the experimenter of 79.4% thinks that the drug permeability that two kinds of penetrating agents combined combine together compared with three strengthens to some extent.Therefore one or both adopting in azone, propylene glycol and oleic acid in nabumetone spray are optimum as transdermal penetration enhancer.
Claims (5)
1. a nabumetone spray, it comprises: nabumetone, transdermal penetration enhancer and excipient, wherein, described transdermal penetration enhancer be selected from azone, oleic acid, propylene glycol, terpenoid substance one or more, and described excipient comprises solvent and solubilizing agent;
Wherein, described solubilizing agent be selected from sodium lauryl sulphate, Tween 80 and PEG400 one or more;
Wherein, described solvent is the ethanol water of 50-100 volume %; And
Wherein, based on the total amount of described nabumetone spray, the amount of described nabumetone is 1 % by weight to 8 % by weight, and the amount of described transdermal penetration enhancer is 1 % by weight to 5 % by weight, and the amount of described excipient is 87 % by weight to 98 % by weight.
2. nabumetone spray according to claim 1, wherein said transdermal penetration enhancer be selected from azone, oleic acid and propylene glycol one or more.
3. nabumetone spray according to claim 1, wherein said solubilizing agent is PEG400.
4. nabumetone spray according to claim 1, wherein, based on the total amount of described nabumetone spray, the amount of described solubilizing agent is 5 % by weight to 60 % by weight, and the amount of described solvent is 30 % by weight to 90 % by weight.
5. prepare a method for the nabumetone spray according to any one of claim 1-4, the method comprises: 1) by even to nabumetone, transdermal penetration enhancer and mixed with excipients; 2) by step 1) the mixture fill that obtains is in aerosol container.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110456544.5A CN103181894B (en) | 2011-12-30 | 2011-12-30 | Nabumetone spraying agent and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110456544.5A CN103181894B (en) | 2011-12-30 | 2011-12-30 | Nabumetone spraying agent and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103181894A CN103181894A (en) | 2013-07-03 |
| CN103181894B true CN103181894B (en) | 2015-07-15 |
Family
ID=48673511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110456544.5A Active CN103181894B (en) | 2011-12-30 | 2011-12-30 | Nabumetone spraying agent and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103181894B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524447A (en) * | 2018-06-06 | 2018-09-14 | 肖耀刚 | A kind of soft tissue injury spray and preparation method thereof |
| CN108543076A (en) * | 2018-07-13 | 2018-09-18 | 邛崃市医疗中心医院 | Prevent the external medicine preparation of rheumatoid arthritis |
| CN108904812A (en) * | 2018-08-27 | 2018-11-30 | 邛崃市医疗中心医院 | With the external drug of the high transdermal characteristic prevention and treatment scapulohumeral periarthritis of carbomer collaboration transdermal agent |
| CN115671052A (en) * | 2022-12-13 | 2023-02-03 | 山东慈卫药业有限公司 | Compound ketoconazole spray for pets and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335379B2 (en) * | 2003-10-10 | 2008-02-26 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| CN101269058A (en) * | 2007-03-20 | 2008-09-24 | 郭德 | Spraying agent containing diclofenac acid and uses thereof |
| CN101296691A (en) * | 2005-08-05 | 2008-10-29 | 努沃研究公司 | Transdermal drug delivery formulation |
| CN101468013A (en) * | 2007-12-25 | 2009-07-01 | 邱芳龙 | Novel use of biguanide-based purine ring derivates in improving medicament effect of analgesia medicament |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7585493B2 (en) * | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| CA2546404A1 (en) * | 2003-11-19 | 2005-06-02 | Acrux Dds Pty Ltd. | Method and composition for treatment or prophylaxis of amyloidosis disorders |
| GB0524961D0 (en) * | 2005-12-07 | 2006-01-18 | Pharmakodex Ltd | Transdermal administration of active agents for systemic effect |
| CA2760186C (en) * | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
-
2011
- 2011-12-30 CN CN201110456544.5A patent/CN103181894B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335379B2 (en) * | 2003-10-10 | 2008-02-26 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| CN101296691A (en) * | 2005-08-05 | 2008-10-29 | 努沃研究公司 | Transdermal drug delivery formulation |
| CN101269058A (en) * | 2007-03-20 | 2008-09-24 | 郭德 | Spraying agent containing diclofenac acid and uses thereof |
| CN101468013A (en) * | 2007-12-25 | 2009-07-01 | 邱芳龙 | Novel use of biguanide-based purine ring derivates in improving medicament effect of analgesia medicament |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103181894A (en) | 2013-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210000761A1 (en) | Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds | |
| CN101554372B (en) | Calcitriol dripping pill and preparation method thereof | |
| CN103181894B (en) | Nabumetone spraying agent and preparation method | |
| US20170333463A1 (en) | Compositions and formulations of glucosamine for transdermal and transmucosal administration | |
| US20160081959A1 (en) | Method of using arginine silicate inositol complex for wound healing or repair | |
| WO2007129162A2 (en) | Pharmaceutical preparations for transdermal use | |
| CN101244027A (en) | Artemether percutaneous drug administration preparation for treating dermatosis | |
| JP7190571B2 (en) | Uses of Bray Aconitine A | |
| CN104688721A (en) | Anti-rheumatoid arthritis drug gel containing paclitaxel liposome and preparation method of gel | |
| IL276838A (en) | Oral formulation and suspension of an oncology drug | |
| CN101496833B (en) | Liquid external preparation for preparing total alkaloids in nux vomica | |
| CN105726586A (en) | External preparation of ginkgo biloba extract and preparation method and application of external preparation | |
| UA125040C2 (en) | Topical phenytoin for use in the treatment of peripheral neuropathic pain | |
| CN100348174C (en) | Oral drop pill in use for clearing away heat and toxic material, relieving inflammation and alleviating pain, and preparation method | |
| KR20230018481A (en) | Topical administration of 2-(diethylamino)ethyl 2-(4-isobutylphenyl)propionate for the treatment of disease | |
| CN101214223B (en) | Closantel or its sodium salt long-acting sustained-release injection and preparation thereof | |
| CN102670624B (en) | Patch for treating rheumatic arthritis and preparation method thereof | |
| CN105878173B (en) | A kind of Sodium Aescinate liniment | |
| CN101269108A (en) | Tripterygium wilfordii total terpene sustained-release dropping pill and preparation method thereof | |
| CN1332669C (en) | Dripping pills for reducing swelling and easing pain and its preparing method | |
| CN1315472C (en) | Motherwort dropping pill and its preparing method | |
| CN1322851C (en) | Tripterygium total terpenoids drop pill and its preparation method | |
| CN101015640A (en) | Dragon's blood dropping pill and its preparing process | |
| CN1343489A (en) | Percutaneous absorption type anticancer medicine to suppress hyperplasia and untoward differentiation of cells | |
| US20140073612A1 (en) | Transdermal delivery system kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 9 floor Patentee after: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee after: PKU HEALTHCARE Corp.,Ltd. Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: SOUTHWEST SYNTHETIC PHARMACEUTICAL Corp.,Ltd. Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221014 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: PKU HEALTHCARE Corp.,Ltd. Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, Beijing, Haidian District Cheng Fu Road 298, founder building, 9 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKU HEALTHCARE Corp.,Ltd. Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
| TR01 | Transfer of patent right |